Matthew Taylor
Stock Analyst at Jefferies
(2.69)
# 2,124
Out of 4,996 analysts
179
Total ratings
61.11%
Success rate
11.4%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SI Shoulder Innovations | Initiates: Buy | $19 | $12.10 | +57.02% | 1 | Aug 25, 2025 | |
| ABT Abbott Laboratories | Upgrades: Buy | $143 → $145 | $133.55 | +8.57% | 17 | Jul 18, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.90 | +0.67% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $72.46 | +42.15% | 2 | Jan 8, 2025 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $76.25 | -8.20% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $318.00 | -29.87% | 14 | Aug 9, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $94.22 | -19.34% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $2.09 | +5,880.86% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $141.48 | -14.48% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $2.40 | +483.33% | 1 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $45 | $12.00 | +275.00% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.46 | +8.70% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $13.20 | +301.52% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $12.06 | +99.00% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $369.02 | -6.51% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $98.24 | +32.33% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $253.37 | -9.22% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $14.04 | +42.45% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $46.00 | +84.78% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $55.70 | +34.65% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $270.27 | -9.35% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $21.98 | +182.07% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $119.99 | +75.01% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $15.02 | -20.11% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $67.10 | +86.29% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $98.18 | -49.07% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $441.12 | -52.39% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $53.44 | +79.64% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $2.01 | +248.26% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $184.60 | +44.10% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $10.68 | +49.81% | 2 | Jul 19, 2017 |
Shoulder Innovations
Aug 25, 2025
Initiates: Buy
Price Target: $19
Current: $12.10
Upside: +57.02%
Abbott Laboratories
Jul 18, 2025
Upgrades: Buy
Price Target: $143 → $145
Current: $133.55
Upside: +8.57%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.90
Upside: +0.67%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $72.46
Upside: +42.15%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $76.25
Upside: -8.20%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $318.00
Upside: -29.87%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $94.22
Upside: -19.34%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $2.09
Upside: +5,880.86%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $141.48
Upside: -14.48%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $2.40
Upside: +483.33%
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $12.00
Upside: +275.00%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.46
Upside: +8.70%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $13.20
Upside: +301.52%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $12.06
Upside: +99.00%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $369.02
Upside: -6.51%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $98.24
Upside: +32.33%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $253.37
Upside: -9.22%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $14.04
Upside: +42.45%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $46.00
Upside: +84.78%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $55.70
Upside: +34.65%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $270.27
Upside: -9.35%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $21.98
Upside: +182.07%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $119.99
Upside: +75.01%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $15.02
Upside: -20.11%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $67.10
Upside: +86.29%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $98.18
Upside: -49.07%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $441.12
Upside: -52.39%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $53.44
Upside: +79.64%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $2.01
Upside: +248.26%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $184.60
Upside: +44.10%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $10.68
Upside: +49.81%